I'm happy to jump in.
As I mentioned, we were able to fund.... We currently have five clinical trials ongoing right now, all testing new and novel treatments. There is one that is launching very soon out of British Columbia that is going to challenge the way that a certain type of ovarian cancer is treated. It will be very interesting to see the results of that—giving PARP inhibitors first, prior to surgery or any other type of treatment, along with a treatment regime of three different types of drugs.
There's also been a really fantastic study in Montreal testing vaccines as treatment, and we're seeing real promise in that.
We have the five clinical trials, but we've also had those 13 preclinical studies, with the ultimate goal in those to lead to clinical trials and be able to bring more treatments to patients faster.
Then, of course, we have the core in the 25 projects based on model development, helping scientists understand how the disease is responding to different types of treatments and responses.
There is a lot of incredible work going on, but this has only been happening for five years. That's a really short time in the span of research. Just to put it in context, 25 years ago there were only three ovarian cancer scientists in all of Canada. Today there are 250-plus. We have some ground to make up, but we're making it up. However, it can only continue with the necessary funding in order to drive that forward.